CEO Dror Chevion gave a KEYNOTE speech at the Health 2.0 Conference which attempts to reimagine the realm of healthcare by uniting some...

The primary efficacy objective of the study was to demonstrate that treatment with Zygosid-50 yields a significant reduction in the...

Glucometer

Concenter Biopharma, together with the SHEBA Medical Center in Israel recently began recruiting patients for the clinical trial using the...

Concenter BioPharma chosen as WINNERS OF THE 2021 BIOTECHNOLOGY AWARDS

The ZYCORDS patent was recently granted by the European Patent Office and was validated in major European countries.